Consolidated Statement Of Income

ASKA Pharmaceutical Holdings CO., Ltd. - Filing #7302029

Concept 2024-04-01 to
2024-09-30
2024-04-01 to
2024-09-30
2024-04-01 to
2024-09-30
2024-04-01 to
2024-09-30
2024-04-01 to
2024-09-30
2024-04-01 to
2024-09-30
2023-04-01 to
2023-09-30
2023-04-01 to
2023-09-30
2023-04-01 to
2023-09-30
2023-04-01 to
2023-09-30
2023-04-01 to
2023-09-30
2023-04-01 to
2023-09-30
Consolidated statement of income
Statement of income
Net sales
28,617,000,000 JPY
151,000,000 JPY
3,640,000,000 JPY
32,371,000,000 JPY
32,409,000,000 JPY
-38,000,000 JPY
3,162,000,000 JPY
31,675,000,000 JPY
28,404,000,000 JPY
31,648,000,000 JPY
-27,000,000 JPY
108,000,000 JPY
Operating expenses
Selling, general and administrative expenses
12,561,000,000 JPY
12,130,000,000 JPY
Operating expenses
Cost of sales
16,463,000,000 JPY
16,461,000,000 JPY
Operating profit (loss)
3,825,000,000 JPY
-4,000,000 JPY
177,000,000 JPY
3,345,000,000 JPY
3,998,000,000 JPY
-652,000,000 JPY
44,000,000 JPY
3,641,000,000 JPY
3,658,000,000 JPY
3,055,000,000 JPY
-585,000,000 JPY
-61,000,000 JPY
Operating expenses
Research and development expenses
3,093,000,000 JPY
2,410,000,000 JPY
Gross profit (loss)
15,907,000,000 JPY
15,186,000,000 JPY
Ordinary profit (loss)
3,312,000,000 JPY
3,096,000,000 JPY
Net sales
Extraordinary income
JPY
2,314,000,000 JPY
Selling, general and administrative expenses
Non-operating income
Interest income
1,000,000 JPY
2,000,000 JPY
Dividend income
148,000,000 JPY
187,000,000 JPY
Other
55,000,000 JPY
34,000,000 JPY
Non-operating income
204,000,000 JPY
224,000,000 JPY
Cost of sales
Non-operating expenses
Interest expenses
22,000,000 JPY
21,000,000 JPY
Other
113,000,000 JPY
158,000,000 JPY
Non-operating expenses
238,000,000 JPY
183,000,000 JPY
Profit (loss) before income taxes
3,312,000,000 JPY
5,410,000,000 JPY
Gross profit
Income taxes - current
602,000,000 JPY
1,424,000,000 JPY
Extraordinary income
Gain on sale of investment securities
JPY
2,314,000,000 JPY
Income taxes - deferred
150,000,000 JPY
-143,000,000 JPY
Income taxes
752,000,000 JPY
1,280,000,000 JPY
Profit (loss)
2,560,000,000 JPY
4,129,000,000 JPY
Profit (loss) attributable to owners of parent
2,560,000,000 JPY
4,129,000,000 JPY
Other comprehensive income
Valuation difference on available-for-sale securities
-115,000,000 JPY
-134,000,000 JPY
Remeasurements of defined benefit plans, net of tax
-32,000,000 JPY
-15,000,000 JPY
Share of other comprehensive income of entities accounted for using equity method
333,000,000 JPY
271,000,000 JPY
Other comprehensive income
185,000,000 JPY
121,000,000 JPY
Profit attributable to
Comprehensive income
2,745,000,000 JPY
4,251,000,000 JPY
Comprehensive income attributable to
Comprehensive income attributable to owners of parent
2,745,000,000 JPY
4,251,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.